ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
L-arginine-induced chronic pancreatitis in mice: Evaluating effects of pirfenidone and simvastatin.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic pancreatitis is a progressive, debilitating condition with no standardized treatment. Pirfenidone and simvastatin are potential therapeutic agents that exert anti-inflammatory and antifibrotic effects on pancreatic acinar cells.
aimTo evaluate the synergistic effects of pirfenidone and simvastatin in an L-arginine-induced chronic pancreatitis model in mice.
methodsA preclinical, 7-week study was performed using a mouse model of L-arginine-induced chronic pancreatitis. The mice were divided into five groups: Normal control; model control; pirfenidone-treated; simvastatin-treated; and combination-treated (pirfenidone + simvastatin). Treatment started in week 3 after disease induction. Mice were euthanized at weeks 4 and 7 for blood collection and tissue sampling for histological and biomarker analysis, including cytokines, oxidative stress markers, and indicators of fibrosis.
resultsCombination therapy significantly reduced levels of tumor necrosis factor-alpha (11.10 ± 1.57 pg/mL
conclusionCombination of pirfenidone and simvastatin demonstrated a synergistic therapeutic effect in reducing inflammation, fibrosis, and oxidative stress in an L-arginine-induced chronic pancreatitis mouse model, suggesting promise for chronic pancreatitis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.